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Abstract
Background: Maternal obesity impacts fetal growth and pregnancy outcomes. To counteract the deleterious
effects of obesity on fertility and pregnancy issue, preconceptional weight loss is recommended to obese women.
Whether this weight loss is beneficial/detrimental for offspring remains poorly explored. Epigenetic mechanisms could
be affected by maternal weight changes, perturbing expression of key developmental genes in the placenta or fetus.
Our aim was to investigate the effects of chronic maternal obesity on feto-placental growth along with the underlying
epigenetic mechanisms. We also tested whether preconceptional weight loss could alleviate these effects.
Results: Female mice were fed either a control diet (CTRL group), a high-fat diet (obese (OB) group), or a high-fat diet
switched to a control diet 2 months before conception (weight loss (WL) group). At mating, OB females presented an
obese phenotype while WL females normalized metabolic parameters. At embryonic day 18.5 (E18.5), fetuses from OB
females presented fetal growth restriction (FGR; −13 %) and 28 % of the fetuses were small for gestational age (SGA).
Fetuses from WL females normalized this phenotype. The expression of 60 epigenetic machinery genes and 32
metabolic genes was measured in the fetal liver, placental labyrinth, and junctional zone. We revealed 23 genes altered
by maternal weight trajectories in at least one of three tissues. The fetal liver and placental labyrinth were more
responsive to maternal obesity than junctional zone. One third (18/60) of the epigenetic machinery genes were
differentially expressed between at least two maternal groups. Interestingly, genes involved in the histone acetylation
pathway were particularly altered (13/18). In OB group, lysine acetyltransferases and Bromodomain-containing protein 2
were upregulated, while most histone deacetylases were downregulated. In WL group, the expression of only a subset
of these genes was normalized.
Conclusions: This study highlights the high sensitivity of the epigenetic machinery gene expression, and particularly
the histone acetylation pathway, to maternal obesity. These obesity-induced transcriptional changes could alter the
placental and the hepatic epigenome, leading to FGR. Preconceptional weight loss appears beneficial to fetal growth,
but some effects of previous obesity were retained in offspring phenotype.
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Background
The worldwide prevalence of obesity in women was
38 % in 2013 [1]. Obesity during pregnancy comprises
increased risks for metabolic and obstetrical complica-
tions (e.g., gestational hypertension and diabetes, and
preeclampsia) but also stillbirth, prematurity, and con-
genital malformations [2]. Fetal growth could be particu-
larly impacted by maternal obesity. Maternal obesity is
associated with macrosomia or, on the contrary, with
fetal growth restriction (FGR) [3–6]. FGR is associated
with a high incidence of metabolic diseases in adulthood
[7, 8], which is consistent with the developmental origins
of health and disease (DOHaD) concept. This concept,
also named “developmental programming” or “condi-
tioning,” states that environmental factors during early
development could predispose an individual to chronic
diseases [9].
Despite the high incidence of FGR in obese women,
little is known about the underlying mechanisms. FGR
could result from insufficient oxygen supply due to dis-
turbed vascularization, increased lipid accumulation, and
macronutrients transport in the placenta, crucial organ
regulating appropriate fetal development [10–12]. Im-
portantly, different placental parts have different func-
tions and cellular populations [13]. The labyrinth is a
zone of active exchange between maternal and fetal
blood, while the junctional zone provides hormone pro-
duction and storage of nutrients that are necessary for
fetal development [13]. The structure and the function
of several organs could be affected in the offspring of
obese mothers. In utero alterations of hepatic develop-
ment and function by maternal obesity could disturb
metabolic homeostasis [14, 15]. The effect of obesity on
organogenesis and gene expression in growth-restricted
fetuses needs further investigation; the current efforts
are indeed focused on FGR induced by poor maternal
nutrition [16].
Modulation of offspring phenotype in response to ma-
ternal environment could be mediated by epigenetic
mechanisms. Epigenetic marks (e.g., DNA methylation,
histone posttranslational modifications) are stable but
reversible covalent modifications that are regulated by a
complex epigenetic machinery. Its actors “write,” “erase”
or “read” epigenetic marks, establishing the epigenome of
the cell in conjunction with environmental factors. This
epigenetic landscape is dynamic during development and
controls gene expression patterns in a tissue-specific man-
ner. Alterations of DNA methylation, histone modifica-
tions and, to a lesser extent, of their regulators were
observed in relation to FGR caused by different factors
[17–22]. Epigenetic disturbances in growth-restricted fe-
tuses in the context of maternal diet-induced obesity need
further investigation. Maternal unbalanced nutrition and
metabolic state could impact certain epigenetic enzymes
in the developing organs of the offspring, affecting the epi-
genome [23, 24]. As epigenetic marks can be transmitted
through generations of cell divisions, epigenetics has
emerged as a plausible mechanism for long-term memory
of environmental insults [23, 25].
To counteract the negative effects of obesity on preg-
nancy outcomes, preconceptional weight loss is cur-
rently recommended to women with high body mass
index [26]. Nevertheless, very few studies have assessed
the consequences of maternal weight loss on fetal
growth [27]. In humans, weight loss between two preg-
nancies reduces the risk of macrosomia [28]. However,
in another cohort, weight loss between the age of
20 years and conception had a negative impact on birth
weight [29]. Thus, the impact of maternal preconcep-
tional weight changes on fetal growth and underlying
epigenetic processes needs to be clarified. Currently,
there is no relevant mouse model to study this import-
ant issue for public health.
Based on the observations that maternal obesity im-
pairs feto-placental development, our aim was to exam-
ine the impact of maternal weight trajectories (obesity or
weight loss) on the expression of epigenetic and meta-
bolic genes in the fetal liver and in the placental laby-
rinth and junctional zone. We showed that maternal
obesity induced FGR, which was associated with an al-
tered expression of histone acetylation modifiers in the
fetal liver and labyrinth, but not in the junctional zone.
In contrast, correction of obesity during the preconcep-
tional period by nutritional intervention normalized fetal
weight and induced an adaptation at the transcriptional
level. This study provides a novel mouse model for investi-
gating the molecular mechanisms of obesity-induced FGR
and highlights the sensitivity of the epigenetic machinery
to maternal nutrition and metabolism.
Results
High-fat diet (HFD) induced severe obesity in female
mice; switching to a control diet (CD) induced weight loss
and normalization of metabolic parameters
Female mice were fed either a CD (control females
(CTRL)) or a HFD (obese females (OB)) for 4 months
during the preconceptional period (Fig. 1). From the
start of the diet and up to mating, OB females put on
weight faster (β = 0.52, P < 0.001) and were heavier than
CTRL females on a CD (P < 0.001, Fig. 2a). OB females
weighed 27 and 36 % more than CTRL females after 2
and 4 months of diet, respectively. After 2 months on a
HFD, we replaced HFD by CD for a subset of the OB fe-
males to induce weight loss (WL females) (Fig. 1). The
weight of WL females was lower than the weight of OB
females as early as 3 days after CD initiation and after-
wards (P < 0.05 at all time points, Fig. 2a). WL females
tended to normalize their weight (P = 0.105, week 19.5,
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P = 0.062, week 21, P = 0.051, week 21.5, P = 0.031, week
22, WL vs. CTRL). However, they remained 5 % heavier
than CTRL females before mating.
The caloric intake of OB females was higher than the
caloric intake of CTRL females during 4 months of pre-
conceptional diet (P < 0.001, Fig. 2b) but OB and CTRL
females had a similar food intake to body weight ratio
(kcal/kg/day) (Additional file 1: Figure S1). WL females
drastically decreased their caloric intake right after the nu-
tritional intervention (P < 0.001, WL vs. CTRL/OB; Fig. 2b)
and normalized this parameter 1 week later (P = 0.15, week
15, WL vs. CTRL; P < 0.05, WL vs. OB) and thereafter.
Metabolic parameters were assessed after 2 and 4 months
of diet (Fig. 1). OB females were hypercholesterolemic,
hyperglycemic, and glucose intolerant compared to CTRL
females (P < 0.001, P < 0.05, and P < 0.001 at each time
point, respectively, Fig. 2c–f). The nutritional intervention
normalized these parameters in WL females.
In summary, OB females were obese and had an im-
paired glucose metabolism and hypercholesterolemia.
Switching to a CD allowed complete restoration of all
these parameters although WL females remained 5 %
heavier than CTRL females before mating.
Obese dams on a HFD gained less weight at term of
pregnancy
To determine the potential effects of maternal obesity
and preconceptional weight loss on fetal outcomes, we
mated CTRL, OB, and WL females after 4 months of
preconceptional diet with males on a standard labora-
tory diet (Fig. 1). Preconceptional diet was maintained
during pregnancy. OB dams had reduced total pregnant
body weight gain and carcass weight compared with CTRL
and WL dams at embryonic day 18.5 (E18.5) (P < 0.001,
Fig. 3a, b). There were no differences between WL and
CTRL dams (P = 0.83 for total weight gain; P = 0.56 for
carcass weight). The maternal group explained 29 % of the
variance in total body weight gain and 37 % of the variance
in carcass weight at E18.5. OB and WL dams had increased
litter size vs. CTRL dams at E18.5 (P < 0.001; CTRL
5.5 ± 2.18, n = 14 litters; OB 6.8 ± 1.99, n = 11 litters;
WL 7.0 ± 2.26, n = 17 litters). There was no difference
in litter size between OB and WL dams (P = 0.13).
Maternal obesity induced fetal growth restriction, while
preconceptional weight loss allowed restoration of fetal
weight
As several studies identified sex-specific effects of mater-
nal obesity on fetuses and placentas, we tested the effect
of sex on fetal and placental weights [12, 30–32]. Sex did
not affect fetal weight (P = 0.17) but affected placental
weight and fetal-weight-to-placental-weight ratio index
(FPI). Male placentas were heavier than female placentas
(P < 0.001; difference in CTRL 11 %, OB 10 %, and WL
7 %), and FPI was lower in males than in females for all
maternal groups (P < 0.001). We therefore adjusted for sex
in the placental weight and FPI analysis only. Moreover,
litter size affected fetal and placental weights (P < 0.001),
and even if it explained only 4.6 and 7.7 % of the variance,
respectively (Additional file 1: Figure S2 and S3), we
adjusted all analyses for this parameter. There were no
differences in the mother’s age at mating between the
three investigated groups (CTRL 26.1 ± 1.94 weeks; OB
25.6 ± 1.83 weeks; WL 25.6 ± 1.71 weeks). Maternal age/
Fig. 1 Experimental design. C57BL/6j females were fed a control diet (CD) or a high-fat diet (HFD) throughout the study. After 2 months of diet,
HFD was switched to CD for the weight loss group. After 2 and 4 months of diet, females’ metabolic parameters (cholesterol, fasting glucose
levels, and glucose tolerance) were measured. Females were mated with males on a standard diet and sacrificed at E18.5, then fetuses and
placentas were weighed and collected
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diet duration correlated with fetal weight and FPI but not
with placental weight (Pearson’s correlation test, r = 0.39,
P < 0.001, r = 0.40, P < 0.001, r = −0.08, P = 0.17, respect-
ively, Additional file 1: Figure S4). All studies were there-
fore adjusted for maternal age, which was also equivalent
to diet duration in our experimental protocol.
We then examined the effect of maternal metabolism
on fetal and placental weights at E18.5. We observed a
13 % reduction of the weight in fetuses of OB dams
compared with CTRL dams (P < 0.001, Fig. 3c). Fetuses
of WL dams had similar weight to fetuses of CTRL dams
(P = 0.17, Fig. 3c) but heavier than fetuses of OB dams
(P < 0.001). Overall, maternal group and age explained
15 and 14 % of the variance in fetal weight, respectively.
We determined the proportion of small for gestational
age (SGA) fetuses, defined as fetal weight <10th percent-
ile of CTRL population. There were 28.4 % of SGA
fetuses in OB dams and 11.8 % in the WL dams (Fig. 3d).
The odds of being SGA was increased in OB group by a
factor of 3.2 (logistic regression, 95 % CI 1.19–9.76,
P = 0.028). In WL group, the odds of being SGA was
not altered compared to CTRL group (P = 0.48). Increase
in maternal age/diet duration for 1 week decreased the
odds by a factor of 0.61 (P < 0.001). Gaussian distributions
of fetal weight in the three maternal groups are available
in Additional file 1: Figure S5.
There was no effect of maternal group on placental
weight at E18.5 (P = 0.42, Fig. 3e). FPI, which represents
placental efficiency, was reduced in the fetuses of OB dams
compared with those of CTRL and WL dams (P < 0.001,
Fig. 3f ). However, WL and CTRL dams had similar
FPI (P = 0.16). Maternal group explained 12 % of the
variance in FPI. In female fetuses, there was a correlation
between fetal and placental weight in all maternal groups
Fig. 2 Body weight and metabolic parameters of OB and WL females during the preconceptional period. a Body weight. (a) P < 0.05 OB vs. CTRL,
(b) P < 0.05 WL vs. CTRL, (c) P < 0.05 WL vs. OB. n = 20 CTRL, 23 OB, 19 WL. b Caloric intake. (a) P < 0.001 OB vs. CTRL, (b) P < 0.001 WL vs. CTRL, (c)
P < 0.05 WL vs. OB. n = 18–20 CTRL, 23 OB, 17–19 WL. c Plasma cholesterol levels after 2 and 4 months of preconceptional diet. NS nonsignificant.
(a) P < 0.001 OB vs. CTRL, (b) P < 0.001 WL vs. CTRL, (c) P < 0.001 WL vs. OB. n = 17–19 CTRL, 22–23 OB, 19 WL. d Fasting glucose level after 2 and
4 months of preconceptional diet. NS nonsignificant. (a) P < 0.05 OB vs. CTRL, (b) P < 0.05 WL vs. CTRL, (c) P < 0.05 WL vs. OB. n = 17–19 CTRL, 23
OB, 19 WL. e Plasma glucose levels during oral glucose tolerance test (OGTT) after 2 months of diet. (a) P < 0.001 OB vs. CTRL, (b) P < 0.001 WL vs.
CTRL, 11–12 females per group. f Plasma glucose levels during OGTT after 4 months of diet. (a) P < 0.001 OB vs. CTRL, (c) P < 0.001 WL vs. OB, 12
females per group. Data are expressed as mean ± St. Dev (a, b, e, f) or as Tukey’s boxplot (c, d)
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(Pearson’s correlation test, adjusting for factor
“mother”: CTRL r = 0.50, Padj = 0.006; OB r = 0.49;
Padj = 0.006; WL r = 0.36, Padj = 0.0063; Additional file
1: Figure S5). In male fetuses, we observed a correl-
ation in WL (r = 0.45, Padj = 0.002), but not in CTRL and
OB groups (r = 0.28, Padj = 0.097 and r = 0.1, Padj = 0.54,
respectively).
Thus, maternal chronic obesity caused FGR in both
sexes and impaired placental efficiency. Preconceptional
weight loss induced by nutritional intervention abolished
this FGR and restored placental efficiency.
Maternal obesity altered gene expression in the fetal liver
and placental labyrinth, but not in junctional zone
To unravel the molecular mechanisms of the impact of
maternal obesity and preconceptional weight loss in
growth-restricted offspring, we assessed the gene expres-
sion at E18.5 using custom TaqMan low-density arrays
(TLDAs). We tested the expression of 60 epigenetic ma-
chinery genes and 32 genes involved in metabolism or in
development (Additional file 2: Table S1). Based on the
literature and our previous studies, these epigenetic
genes were selected because of their implication in
metabolic processes and obesity or type 2 diabetes [30,
33]. Some of the metabolic genes assessed in our study
are known targets of developmental conditioning, and
for a subset of these genes, the epigenetic alterations are
documented in this context. A description of the selec-
tion criteria of genes for the custom TLDA design is
available in Additional file 3.
The vast majority of expression studies are performed in
whole placentas, but epigenetic and metabolic processes
Fig. 3 Body weight and fetal and placental weights in OB and WL dams at E18.5. a Dams pregnant body weight gain (percentage of initial
weight). NS nonsignificant. (a) P < 0.001 OB vs. CTRL. (c) P < 0.001 WL vs. OB. n = 13 CTRL, 11 OB, 17 WL. b Dams carcass weight (percentage of
initial weight) at sacrifice. NS nonsignificant. (a) P < 0.001 OB vs. CTRL, (c) P < 0.001 WL vs. OB. n = 13 CTRL, 10 OB, 16 WL. c Fetal weight. NS
nonsignificant. (a) P < 0.001 OB vs. CTRL. (c) P < 0.001 WL vs. OB. Data from males and females were combined as there was no effect of sex on fetal
weight. n = 75 CTRL, 74 OB, 119 WL. d Proportion of small for gestational age (SGA) fetuses. Data from males and females were combined as there
was no effect of sex on fetal weight. CTRL (n = 7 SGA/75 fetuses), OB (n = 21/74), WL (n = 14/119). Maternal obesity: odds ratio (OR) of being SGA = 3.2
(95 % CI 1.19–9.76, P = 0.028). e Placental weight. (s) P < 0.001 males vs. females. n = 36 CTRL F, 39 CTRL M, 35 OB F, 39 OB M, 61 WL F, 58 WL M.
f Fetal-weight-to-placental weight ratio index. (a) P = 0.001 OB vs. CTRL. (c) P < 0.001 WL vs. OB. (s) P = 0.001 males vs. females. n = 36 CTRL F, 39
CTRL M, 35 OB F, 39 OB M, 61 WL F, 58 WL M
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may not be the same in different placental layers
since they have different functions and cell popula-
tions [30, 34, 35]. The liver is a major organ regulating
the metabolic processes and it is particularly affected
by obesity [14, 15]. Thus, the expression study was
performed in placental labyrinth and junctional zone
separately, as well as in the fetal liver, as we also aimed
to evaluate the impact of maternal nutrition on fetal
tissues.
Hierarchical clustering based on mean gene expression
revealed that gene expression was affected by maternal
diet in the liver and labyrinth: the OB group clustered
away from the CTRL and WL groups (Fig. 4a, b). The
effect of obesity was weaker in the junctional zone as
OB males and females clustered with WL and CTRL
males (Fig. 4c). In the liver, groups clustered according
to maternal diet while in placental layers, CTRL and WL
groups clustered according to fetal sex. Thus, maternal
obesity affected the mean expression of all tested genes
in the fetal liver and labyrinth, while maternal weight
loss restored it.
We showed that 23 genes were significantly altered by
maternal weight trajectories in at least one of three tis-
sues (Table 1). The full list of mean expression level per
gene and per group and adjusted p values are presented
in Additional file 4: Table S2.
The expression of Kdm5d (Jarid1d) and Uty genes,
which are localized on the Y chromosome, was restricted
to male samples. Their paralogs located on the X
chromosome (Kdm5c/Jarid1c and Kdm6a/Utx), and
which partially escape X inactivation, were not differen-
tially expressed between males and females, except for
Kdm6a in the junctional zone (p = 0.003). Two other
genes showed sex differences in this tissue independent
of maternal dietary group: Bdnf and Lpl were also more
expressed in female (P = 0.039 and 0.033, respectively).
We then pooled male and female data from the same
maternal group to assess the effect of maternal diet on
gene expression. Maternal age did not correlate with
gene expression in any of the three investigated tissues
(Pearson’s correlation test; P > 0.05 for all genes).
Maternal obesity and weight loss altered the expression
of epigenetic machinery genes in the fetal liver
Maternal weight trajectories affected the transcription of
nine epigenetic genes in the liver (Fig. 5, Table 1). Ex-
pression of the histone deacetylase Hdac2 was reduced
in OB fetuses compared to CTRL fetuses (Table 1, Fig.
5e). On the contrary, expression of the lysine acetyl-
transferases Kat2a (Gcn5), Kat3a (Creb binding protein),
Kat6b (Myst4) and Kat13d (Clock), the arginine methyl-
transferases Prmt1 and Prmt7, the histone deacetylase
Hdac6, and the bromodomain protein Brd2 was in-
creased in fetuses from OB dams. Maternal weight loss
Fig. 4 Hierarchical clustering of gene expression in the fetal liver,
placental labyrinth, and junctional zone. The clustering is based on
the expression of 80 genes in the liver (a), 86 genes in the labyrinth
(b), and 89 genes in the junctional zone (c) in CTRL, OB, and WL
females. Data are represented as Pearson’s correlation distance.
Non-amplified genes were removed from analysis. F females, M males
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induced various transcriptional responses of epigenetic
machinery genes. On the one hand, Brd2 expression
remained increased in WL compared to CTRL fetuses,
showing no normalization of its expression (Fig. 5g).
Expression of Hdac2 and Kat3a tended to remain al-
tered in the liver of WL fetuses (Padj = 0.065 and Padj =
0.055, respectively, WL vs. CTRL). On the other hand,
expression of Kat2a, Kat6b, Kat13d, Hdac6, Prmt1,
and Prmt7 was similar in WL and CTRL fetuses.
Therefore, maternal weight loss restored the expres-
sion of some of the genes that were altered by mater-
nal obesity, but not of all.
Among the investigated metabolic genes, only glucoki-
nase (Gck) was affected. Its expression was reduced in
the liver of OB fetuses compared to that of CTRL and
normalized in WL fetuses (Table 1, Fig. 6a).
Maternal obesity and weight loss altered the expression
of epigenetic machinery and metabolic genes in the
placenta
Maternal obesity and weight loss altered the expression of
12 epigenetic genes in the placental labyrinth and one gene
in junctional zone (Fig. 7, Table 1). Expression of the lysine
acetyltransferases Kat1 (Hat1), Kat3b (Ep300), and Kat13b
(Ncoa3) was higher in the labyrinth of OB dams compared
to that of CTRL dams (Fig. 7a, c, e). Expression of the ly-
sine methyltransferase Kmt1d (Ehmt1) and the histone dea-
cetylases Hdac3 and Hdac10 was reduced in the labyrinth
of OB dams (Table 1, Fig. 7g, h). In WL dams, responses in
the placenta highly differed between the genes. There was
no restoration of expression for Kat1, Kat3b, and Kat13b.
On the contrary, Kmt1d, Hdac3, and Hdac10 expression
was restored.
Table 1 Differentially expressed genes in the fetal liver, placental labyrinth, and junctional zone at E18.5
Tissue Gene CTRL group OB group WL group P value
OB vs. CTRL WL vs. CTRL WL vs. OB
Fetal liver Kat2a (Gcn5) 2.92 ± 0.90 4.77 ± 1.48 4.14 ± 1.51 ↗ 0.004 0.118 0.622
Kat3a (Crebbp) 0.71 ± 0.19 1.14 ± 0.34 1.04 ± 0.37 ↗ 0.008 0.055 0.745
Kat6b (Myst4) 0.97 ± 0.29 1.65 ± 0.48 1.26 ± 0.41 ↗ 0.004 0.209 0.209
Kat13d (Clock) 2.19 ± 0.59 3.67 ± 0.89 3.16 ± 1.23 ↗ <0.001 0.307 0.445
Hdac2 0.43 ± 0.17 0.20 ± 0.07 0.26 ± 0.13 ↘ 0.004 0.065 0.496
Hdac6 1.44 ± 0.43 2.29 ± 0.71 1.78 ± 0.74 ↗ 0.012 0.445 0.339
Brd2 0.25 ± 0.07 0.34 ± 0.07 0.37 ± 0.10 ↗ 0.039 0.024 0.731
Prmt1 0.50 ± 0.15 0.78 ± 0.21 0.61 ± 0.23 ↗ 0.008 0.431 0.279
Prmt7 7.1 ± 2.6 11.6 ± 3.9 8.5 ± 3.0 ↗ 0.016 0.496 0.166
Gck 0.81 ± 0.56 0.26 ± 0.24 0.76 ± 0.61 ↘ 0.031 0.940 0.088
Lepr 0.22 ± 0.09 0.25 ± 0.07 0.17 ± 0.05 0.637 0.377 ↘ 0.039
Labyrinth Kat1 (Hat1) 0.024 ± 0.011 0.041 ± 0.013 0.037 ± 0.010 ↗ 0.012 ↗ 0.029 0.463
Kat3a (Crebbp) 1.22 ± 0.42 1.49 ± 0.43 1.84 ± 0.60 0.215 ↗ 0.029 0.192
Kat3b (Ep300) 0.012 ± 0.006 0.030 ± 0.014 0.029 ± 0.014 ↗ 0.003 ↗ 0.006 0.907
Kat13b (Ncoa3) 0.045 ± 0.022 0.084 ± 0.033 0.087 ± 0.028 ↗ 0.017 ↗ 0.003 0.871
Hdac2 0.35 ± 0.15 0.23 ± 0.15 0.18 ± 0.08 0.124 ↘ 0.014 0.448
Hdac3 4.03 ± 1.41 2.60 ± 0.62 3.81 ± 1.43 ↘ 0.021 0.797 0.053
Hdac10 0.22 ± 0.08 0.10 ± 0.05 0.22 ± 0.10 ↘ 0.003 0.978 ↗ 0.003
Sirt4 0.32 ± 0.14 0.23 ± 0.07 0.37 ± 0.16 0.124 0.478 ↗ 0.046
Brd2 0.73 ± 0.26 0.91 ± 0.18 1.06 ± 0.31 0.124 ↗ 0.036 0.266
Kmt1d (Ehmt1) 2.09 ± 0.74 1.34 ± 0.37 2.50 ± 1.15 ↘ 0.029 0.402 ↗ 0.017
Mbd5 0.031 ± 0.010 0.022 ± 0.007 0.035 ± 0.013 0.053 0.480 ↗ 0.021
Mecp2 0.035 ± 0.012 0.029 ± 0.010 0.045 ± 0.012 0.247 0.112 ↗ 0.007
Hsd11β1 49.7 ± 25.5 26.1 ± 13.8 52.1 ± 32.0 ↘ 0.046 0.892 0.065
Irs1 0.71 ± 0.36 0.38 ± 0.19 0.65 ± 0.41 ↘ 0.043 0.777 0.124
Tph1 0.021 ± 0.010 0.012 ± 0.006 0.021 ± 0.009 ↘ 0.033 0.978 ↗ 0.04951
Junctional zone Kat3b (Ep300) 0.029 ± 0.008 0.042 ± 0.012 0.045 ± 0.012 0.101 ↗ 0.040 0.743
Data are represented as mean expression levels ± St.Dev. When the p value was significant, an arrow showing the sense of variation was added
(↘ downregulation, ↗ upregulation)
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Expression of Sirtuin 4, Mecp2, and Mbd5 was higher
in WL than in OB labyrinth, but similar to CTRL
(Table 1, Fig. 7i). Finally, some genes were not altered by
maternal obesity but by maternal weight loss: Kat3a and
Brd2 were upregulated and Hdac2 was downregulated in
the labyrinth; Kat3b was upregulated in the junctional
zone (Fig. 7b, d, f, j). For these four genes, the medians
and the distributions in OB group were intermediate be-
tween CTRL and WL groups.
We showed that the expression of hydroxysteroid 11-
beta dehydrogenase 1 (Hsd11β1), insulin receptor sub-
strate 1 (Irs1), and tryptophan hydroxylase 1 (Tph1) was
downregulated in the placental labyrinth of OB dams
(Table 1, Fig. 6b–d). There was no difference between
WL and CTRL for these metabolic genes. None of the
investigated metabolic or developmental genes were af-
fected in the junctional zone.
Thus, the expression of 30 % of epigenetic machinery
genes (18 out of 60 studied) was altered by maternal
weight trajectories in three tissues. Fifteen percent of
genes (9/60) was differentially expressed in the fetal liver,
20 % (12/60) in the labyrinth, and 1.7 % (1/60) in the junc-
tional zone. The histone acetylation pathway (KATs,
HDACs, and BRDs) was particularly altered: 78 % of dif-
ferentially expressed genes in the liver (7/9), 75 % in the
labyrinth (9/12), and the only gene in the junctional zone.
Fig. 5 Genes implicated in histone acetylation are differentially expressed in the fetal liver at E18.5. We assessed the expression level of 60 genes
of the epigenetic machinery using TaqMan low-density arrays. The expression of Kat2a (a), Kat3a (b), Kat6b (c), Kat13d (d), Hdac2 (e), Hdac6 (f),
and Brd2 (g) was affected by maternal obesity. (a) Padj < 0.05 OB vs. CTRL, (b) Padj < 0.05 WL vs. CTRL. CTRL (n = 16), OB (n = 14), WL (n = 16)
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Maternal obesity had an important effect on the ex-
pression of metabolic and epigenetic genes in the fetal
liver and placental labyrinth, but not in the junctional
zone. Maternal preconceptional weight loss allowed a
global restoration of transcription to CTRL levels. How-
ever, the expression of certain genes (for example, Kat1,
Kat3b, and Kat13b in the labyrinth and Brd2 in the
liver) was not restored.
Discussion
In the present study, we showed that maternal chronic
obesity lead to FGR at E18.5, while the weight loss in-
duced by a nutritional intervention performed in precon-
ceptional period allowed a partial fetal weight restoration.
These phenotypic changes were associated with a tran-
scriptional response in the fetal liver and placental laby-
rinth: we showed that 23 genes were significantly altered
by maternal weight trajectories in at least one of three tis-
sues between two maternal groups (Fig. 8). Our results
identified that epigenetic machinery gene expression is
clearly sensitive to maternal weight trajectories, especially
for genes involved in histone acetylation.
Maternal obesity-induced FGR is associated with altered
expression of epigenetic modifiers in the fetal liver and
placental labyrinth
In our model, OB mice were severely obese and presented
the characteristics of metabolic syndrome after 4 months
of HFD. This resulted in FGR at E18.5, which is consistent
with the previous studies in mice [11, 15, 36, 37].
However, in some mouse models, fetuses from OB dams
displayed an overgrowth, and it associated with altered
placental transport [34, 38]. These discrepancies could be
explained by differences in diet composition, especially by
high-sugar content. In humans and rats, maternal obesity
also associates with an elevated fetal weight [3, 4, 39]. As
maternal obesity associates also with FGR in humans, our
study provides a mouse model for investigation of the mo-
lecular mechanisms of this pathology, which remain un-
known [6].
Maternal HFD alters hepatic function and structure in
the fetus [14, 15]. In OB dams, we report reduced tran-
scription of Gck, the enzyme controlling the synthesis of
hepatic glycogen and implicated in type 2 diabetes. Gck
expression could remain reduced after birth and lead to
impaired glucose metabolism [40, 41]. Placental function
is also affected by obesity or HFD [11, 12, 34, 38, 42,
43]. In our study, Hsd11β1, Irs1, and Tph1 were down-
regulated in the labyrinth of OB dams, suggesting that
alterations of placental function could contribute to
FGR. Hydroxysteroid dehydrogenases 11β control the
passage of glucocorticoids from the mother to the fetus.
In humans, placental expression of HSD11β1 is associ-
ated with birth weight [44]; placental HSD11βs expres-
sion is reduced in SGA neonates [45]. Impaired
placental insulin signaling is associated with obesity, ges-
tational diabetes mellitus, or intrauterine growth restric-
tion (IUGR) [46, 47]. Insulin regulates placental growth,
vascularization, glycogen, and lipid storage [48]. Reduced
expression of Irs1 in OB dams could lead to insulin
Fig. 6 Maternal weight trajectories affect the expression of genes implicated in metabolism. We assessed the expression level of 32 genes
implicated in metabolism or development using TaqMan low-density arrays. The expression of glucokinase (a) in the fetal liver and hydroxysteroid
11-β dehydrogenase 1 (b), insulin receptor substrate 1 (c), and tryptophan hydroxylase 1 (d) in the placental labyrinth was affected by maternal
obesity or weight loss at E18.5. (a) Padj < 0.05 OB vs. CTRL, (c) Padj < 0.05 WL vs. OB. CTRL (n = 16), OB (n = 14), WL (n = 16)
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Fig. 7 Genes implicated in histone acetylation are differentially expressed in the placenta at E18.5. We assessed the expression level of 60
epigenetic machinery genes using TaqMan low-density arrays. The expression of Kat1 (a), Kat3a (b), Kat3b (c), Kat13b (e), Hdac2 (f), Hdac3 (g),
Hdac10 (h), Sirt4 (i), and Brd2 (j) was affected by maternal obesity and weight loss in the labyrinth. Only Kat3b (d) was differentially expressed in
the junctional zone. (a) Padj < 0.05 OB vs. CTRL, (b) Padj < 0.05 WL vs. CTRL, (c) Padj < 0.05 WL vs. OB. CTRL (n = 16), OB (n = 14), WL (n = 16)
Panchenko et al. Clinical Epigenetics  (2016) 8:22 Page 10 of 19
resistance in placental labyrinth and affect these processes.
Finally, downregulation of Tph1 could impair the trans-
formation of maternal tryptophan to serotonin, a process
that is necessary for proper fetal brain development [49, 50].
Metabolic diseases are associated with alteration of
epigenetic marks [51]. A key finding in this study is that
maternal obesity has a major impact on the expression
of epigenetic regulators in the fetal liver and placental
labyrinth at term. The actors of the histone acetylation
pathway were particularly affected. Some families of epi-
genetic modifiers were not affected by obesity in our
study: DNA methyltransferases, TET methylcytosine
dioxygenase (TET) proteins, methyl-binding proteins,
and lysine demethylases. But this does not preclude
changes at previous developmental stages.
Transcript levels of arginine methyltransferases Prmt1
and Prmt7 were upregulated in the liver of OB fetuses.
Prmts, which catalyze the methylation of arginine his-
tone residues, are implicated in hepatic gluconeogenesis
[52]. Prmt1 dimethylates the arginines on forkhead box
protein O1 (FOXO1), inducing the translocation of this
transcription factor into the nucleus and activation of its
target metabolic genes [53]. No implication of Prmt7 in
hepatic metabolism or development is known. Implica-
tions of the histone arginine methyltransferase activity in
FGR or in response to maternal nutritional environment
remain to be determined. Only one of the seven studied
lysine methyltransferases was differentially expressed in
our study: Kmt1d was downregulated in the labyrinth of
OB dams. No implication of this lysine methyltransferase
in placental biology has yet been reported.
Preconceptional weight loss is beneficial to fetal growth
and induces an adaptation at the transcriptional level
To our knowledge, it is the first mouse model to study
the effects of preconceptional weight loss induced by
nutritional intervention on fetal growth and on the tran-
scriptional response in fetal and placental tissues. Despite
the normalization of maternal phenotype at conception
(Fig. 2), fetuses of WL dams presented transcription differ-
ences compared with fetuses of CTRL dams.
The nutritional intervention and preconceptional
weight loss restored the FGR observed in OB fetuses.
Interestingly, the proportion of SGA fetuses was com-
parable to the proportion of SGA fetuses from CTRL
dams. The first human cohort studies point at rather
beneficial effects of maternal weight loss on fetal out-
comes, namely a lower risk of large for gestational age
(LGA) infants compared to obese patients [27, 28, 54].
In sheep, maternal obesity induced macrosomia and ele-
vated heart, liver, and perirenal adipose tissue weights. A
nutritional intervention normalized the fetal and organ
weights [55]. In rat studies, there was no effect of mater-
nal obesity or weight loss on fetal weight [56, 57]. Taking
into account our results, preconceptional weight loss ap-
pears beneficial for fetal growth, counteracting the ad-
verse effects of maternal obesity.
In our expression study, we observed different profiles
of transcriptional response to maternal weight loss:
mRNA levels of a subset of genes were completely or
partially normalized, while other genes remained altered.
Overall, the placenta and fetal liver in WL group pre-
sented an adaptation in gene expression with high indi-
vidual variability for some genes.
Finally, some genes were differentially expressed only
in WL group: the methyl-DNA binding proteins Mecp2
and Mbd5 were upregulated in the labyrinth of WL
compared with CTRL and OB. These DNA methylation
“readers” are implicated in obesity (MeCP2) and glucose
homeostasis regulation (MBD5) [58–60]. In the placenta
of calorie-restricted mice, MeCP2 binding to hyper-
methylated CpG island of Glut3 was enhanced [61].
We observed a restoration of Gck mRNA levels in the
fetal liver of WL offspring, and a restoration of Hsd11β1,
Irs1, and Tph1 levels in the placental labyrinth. Similar
results were obtained for Hsd11β1 in a sheep model of
maternal obesity and nutritional preconceptional inter-
vention [62]. The normalization of expression of these
genes involved in glucose, glucocorticoid and serotonin
metabolism, and insulin signaling by maternal weight
loss could abolish the negative effects induced by mater-
nal obesity.
In this study, maternal obesity, despite the nutritional
intervention prior to conception, was retained in the gene
expression pattern. WL females were severely obese
throughout their puberty, when HFD consumption and
high adiposity could have affected their gonads. Obesity
causes lipid accumulation, mitochondrial dysfunction, and
chromosomal abnormalities in oocytes, as well as a modi-
fication of follicular liquid content [63, 64]. This can
Fig. 8 Differentially expressed genes in the fetal liver, placental
labyrinth, and junctional zone. Venn diagram shows the names of
the genes altered by maternal weight trajectories in the three tissues.
Metabolic genes are represented in black, methyl CpG-binding proteins
in violet, arginine methyltransferases and lysine methyltransferases in
blue, histone deacetylases in green, lysine acetyltransferases in red, and
bromodomain-containing proteins in pink
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induce FGR and developmental defects [65]. The negative
consequences of maternal obesity could be transmitted, at
least in part, via alteration of oocyte function and epige-
nome. Methylation levels of genes involved in the lipid
metabolism could be transmitted to the blastocyst and to
adult progeny in mice [66]. In another study, maternal
HFD and obesity induces hypermethylation of Lep and hy-
pomethylation of Pparα in the oocytes and in the liver of
adult offspring [67]. The oocyte epigenetic machinery and
acetylation levels are sensitive to maternal diabetes [68].
Therefore, in our study, despite the normalization of me-
tabolism by nutritional intervention, some epigenetic
marks affected by obesity could be retained in the
WL group. Weight loss could also trigger the addition
of novel epigenetic marks in oocytes. These epigenetic
alterations could provide a mechanism that explains
the “memorization” of an obesogenic environment.
The balance between “writers” and “erasers” of histone
acetylation could play a role in obesity-induced FGR
In our expression profiling, we studied the transcription
of 29 genes involved in histone acetylation (KATs,
HDACs, and BRDs), out of 60 epigenetic genes (48 %).
Remarkably, 78 % of differentially expressed epigenetic
genes in the fetal liver (7 out of 9) and 75 % in the laby-
rinth (9 out of 12) are involved in histone acetylation.
The only differentially expressed gene in the junctional
zone (Kat3b) is also involved in acetylation pathway.
The three genes in common between the liver and laby-
rinth and the gene differentially expressed in the two
placental layers are involved in histone acetylation.
Seven members of KAT family, “writers” of lysine acetyl-
ation, were upregulated in the fetal liver and placental
labyrinth of OB dams. Interestingly, their expression was
restored in the fetal liver (Kat2a, Kat3a, Kat6b, and
Kat13d) of WL dams, but there was clearly no restor-
ation in the labyrinth (Kat1, Kat3a, Kat3b, and Kat13b).
Moreover, the expression of the majority of HDACs
(Hdac2, Hdac3, and Hdac10) that mediate the opposite
reaction was reduced in the fetal liver and placental
labyrinth of OB dams.
Therefore, we observed a disruption in the balance be-
tween the expression of “writers” and “erasers” of lysine
acetylation in offspring from obese mother at term of
gestation (Table 2). This could lead to an increased level
of histone acetylation in FGR offspring of OB dams. In
primates, global levels of histone 3 (H3)K14ac were up-
regulated in the liver at term and after birth in the case
of chronic maternal HFD consumption [69]. This hyper-
acetylation is consistent with reduced expression and en-
zymatic activity of Hdac1 and Sirt1 [70]. In mice,
maternal HFD increased the level of H3K14ac in the
fetal liver at E18.5, and this effect persisted after birth
[71]. Interestingly, expression of Hdac1, Hdac3, and
Sirt1 was unaltered at the same stage. In rats, the Pepck
gene implicated in gluconeogenesis is enriched in H4ac
in the liver of fetuses from dams on a HFD, which is
consistent with its high expression and fetal hypergly-
caemia [39]. In diabetic mice, the expression of KATs
was upregulated in oocytes, while the expression of
HDACs was downregulated, as in our study, and the dy-
namics of acetylation at different lysine residues was dis-
turbed during oocyte maturation [68].
These studies mainly tested the expression of
acetylation-related genes. One purpose of our study was
to analyze the expression of different families of epigen-
etic modifiers. The only other extensive report focused
on 67 epigenetic modifiers in transcriptomic data from
fetal lung, liver, kidney, heart, and placenta of IUGR fe-
tuses, induced by low-protein maternal diet in rats [72].
Histone acetylation modifiers were unchanged while
DNA methyltransferases (DNMTs) were differentially
expressed in the fetal liver and HDACs in the lung.
Therefore, maternal undernutrition or overnutrition
could affect different biological processes yet both result-
ing in FGR.
Some of the differentially expressed KATs or HDACs
revealed in our study are implicated in metabolic pro-
cesses and associated with metabolic diseases, according
to different studies in mice and humans. Hdac2 and
Hdac6 are involved in adipogenesis [73]. HDAC3 is an
important regulator of hepatic lipid metabolism in a circa-
dian manner and invalidation of its gene induces hepatic
steatosis [74]. Single nucleotide polymorphisms in
KAT13D (CLOCK) gene are associated with obesity and
weight loss success in humans [75, 76]. CLOCK is a major
circadian regulator: in mice, its mutation disrupts the cir-
cadian rhythms and induces a metabolic syndrome [77].
Kat13b is involved in energy expenditure and therefore
obesity [78]. Kat3a is implicated in diabetes by acting on
Table 2 Maternal weight trajectories affect the expression of genes involved in histone acetylation
Writers: KATs Erasers: HDACs Readers: Brd2
OB WL OB WL OB WL
Fetal liver ↑ Restoration ↑ or ↓ No restoration (trend)/restoration ↑ No restoration
Labyrinth ↑ No restoration ↓ No restoration/restoration = ↑
Junctional zone = ↑ - - - -
↑ upregulation, ↓ downregulation, = no significant difference, - no differential expression in this tissue, KAT lysine acetyltransferases, HDAC histone deacetylases,
BRD bromodomain-containing proteins
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the transcription of gluconeogenetic genes [79]. Kat3b
regulates the expression of genes involved in lipogenesis
and gluconeogenesis in the liver [80]. Thus, KATs and
HDACs have important roles in metabolism and their al-
teration in obese offspring could indicate major changes
in placental and hepatic function.
Bromodomain proteins recognize acetylated lysines
and recruit other enzymes to form a multiprotein com-
plex that further enhances transcriptional activity [81].
Brd2 is a negative regulator of adipogenesis via tran-
scriptional repression of Pparγ. Heterozygous mice inva-
lidated for Brd2 are obese and have surprisingly better
glucose tolerance [82]. The meaning for the increased
Brd2 expression in OB group observed in our study
(Table 2, Fig. 5) remains to be determined.
Overall, our results show that epigenetic machinery
genes are sensitive to maternal environment and that his-
tone acetylation pathway is particularly affected. Epigen-
etic modifiers should be considered when studying the
offspring’s response to maternal metabolic disturbances.
Limitations and strength of the study
In this study, we used a mouse model of obesity-induced
FGR, relevant for the investigation of epigenetic mecha-
nisms underlying this pathology, in relation to feto-
placental development. This is also the first report of the ef-
fects of preconceptional maternal weight loss induced by
nutritional intervention on feto-placental growth and gene
expression at term. This important contribution highlights
the consequences of maternal body weight changes on fetal
outcomes and molecular processes, providing evidence to
the elaboration the preconceptional counseling for obese
women. In our nutritional protocol, we used well-
controlled purified HFD containing 59.9 % calories from
lipids (mainly saturated and monounsaturated fatty acids).
This diet is largely used in metabolic studies in rodents and
is different from the “Western diet” characterized by a
high-lipid and high-sucrose content [36, 38]. Dietary lipids
can have a direct impact on gene transcription by regula-
tion of transcription factors and epigenetic enzymes [24,
83]. However, it is not possible to distinguish the proper ef-
fects of maternal obesity (hormonal and inflammatory fac-
tors, insulin resistance, and hyperglycemia) and that of
dietary lipids in our study. Others tried to address this issue
showing differential effects of maternal adiposity and HFD
on offspring phenotype, but the effects of lipids on epigen-
etic processes during early development need further inves-
tigation [84, 85]. Another important point to notice is that
in our model, 7 weeks of mating were necessary to obtain a
large enough sample size. We therefore included maternal
age/diet duration (indistinguishable according to our proto-
col) in our statistical model. Interestingly, the proportion of
variance in fetal weight and FPI explained by the maternal
age are comparable to the proportion of variance explained
by group. This highlights the relevance of maternal age/diet
duration for fetal weight and the importance to include it
as a covariate.
In our expressional screening, we used a high-output re-
verse transcription (RT)-real-time polymerase chain reac-
tion (qPCR) technique that simultaneously assessed 96
transcripts. We have studied 60 epigenetic machinery
genes, which gives a large overview of the maternal impact
on epigenetic regulation processes. These genes were
chosen based on their implication in metabolic processes
or on our previous study where the effect of maternal
HFD during pregnancy showed an altered expression of
seven epigenetic genes [30]. Our goal was to study differ-
ent families of epigenetic modifiers (DNMTs, TETs, lysine
methyltransferases (KMTs), lysine-specific demethylases
(KDMs), KATs, HDACs, BRDs) because the literature was
particularly focused on histone acetylation and DNA
methylation. However, some interesting epigenetic fam-
ilies were not taken into account, like the gene-encoding
proteins from the polycomb or tritorax families, or
nucleosome remodelers, such as switch/sucrose non-
fermentable (SWI/SNF). The expression of these genes
has never been studied in the context of obesity. More-
over, the expression changes reported here are transcript
levels. There may be differences between mRNA levels
and proteins level or enzymatic activity. In other studies,
Hdac1 and Sirt1 mRNA and protein levels were both af-
fected in the same direction in the context of maternal
obesity or HFD [69, 70].
The originality of our study was to compare different
parts of the placenta—labyrinth and junctional zone—-
which have different structures, cellular content, and
function. Indeed, we observed a striking difference in
terms of gene expression in these two placental layers,
highlighting that obesity could have plausible different
impacts on them. We observed a smaller transcriptional
response in junctional zone in comparison with laby-
rinth. A plausible explanation could be that the laby-
rinth, due to its intimate contact with maternal blood, is
more reactive at the transcriptional level, in order to
adapt to a dynamic environment. Interestingly, the only
affected gene in the junctional zone (Kat3b) is differen-
tially expressed in a similar pattern in the labyrinth.
KAT3b is implicated in preeclampsia, a disease associ-
ated with placental insufficient vascularization, and with
the regulation of placental Hsd11β2 expression via ele-
vated H3K9ac and H3K27ac in humans [86, 87]. Our
study highlights a potential important role of KAT3b in
the placenta in response to maternal metabolism. Its epi-
genetic targets need further investigation.
Conclusions
In our mouse model, maternal obesity induced FGR and
reduced placental efficiency at term. These phenotypic
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changes were associated with alterations of the expres-
sion of genes involved in epigenetic processes in the fetal
liver and placenta. Nutritional intervention during the
preconceptional period allowed maternal weight loss
and the normalization of metabolic parameters at mat-
ing. In the offspring of WL mothers, fetal growth was
partially restored and the transcription was normalized
only for a subset of genes affected by maternal obesity.
Thus, the history of maternal obesity has an impact on
fetal growth and transcriptional activity. The epigenetic
machinery is highly sensitive to maternal weight trajec-
tories, which could lead to an altered epigenome in the
offspring. Histone acetylation modifiers represented a
major part of the differentially expressed genes in OB
and WL groups that could account for reminiscence of
the obese status.
This study highlights the importance of investigating
the mechanisms of regulation of histone marks in re-
sponse to environmental insults. The link between his-
tone modifiers, histone acetylation levels, and placental
and hepatic function should be established. Alteration of
the epigenome early during ontogenesis, could be a
mechanism of “memorization” of the environment in
utero, contributing to particular gene expression pat-
terns and thus to adult phenotype establishment. It
could be an underlying mechanism explaining the condi-
tioning of the offspring health later in life [9, 88]. Ad-
vances in this direction should help to unravel the
molecular mechanisms of developmental conditioning
induced by maternal weight trajectories.
Methods
Animal experiments
The COMETHEA ethical committee (Comité d’éthique
pour l’expérimentation animale), registered with the na-
tional Comité National de Réflexion Ethique sur l’Expér-
imentation Animale under the no. 45 approved this
protocol (visa 12/062). Four-week-old female and 7-
week-old male C57Bl/6J OlaHsd mice were received
from Harlan Laboratory (Venray, Netherlands) and
housed in Unité d'Infectologie Expérimentale des Ron-
geurs et Poissons (IERP; INRA, Jouy-en-Josas, France).
After 1 week of adaptation, the mice were placed in indi-
vidual cages at controlled temperature (22 ± 2 °C) with a
12-h-light/12-h-dark cycle. Mice had ad libitum access
to water and food, and paper towel was provided for
nest building.
Five-week-old control females (CTRL) were fed a con-
trol diet (CD, 10 % from fat, 70 % from carbohydrates,
20 % from protein; #D12450K) and obese females (OB)
were fed a high-fat diet (HFD, 59.9 % from fat, 20.1 %
from carbohydrates, 20 % from protein; #D12492) during
4 months before conception and throughout gestation
(Fig. 1). Diets were purchased in pellet form from
Research Diets (New Brunswick, NJ, USA). After 2 months
of HFD (at 14 weeks of age), a subset of the OB females
was placed on a CD in order to induce a weight loss (WL
group) for the remaining 2 months before conception.
Overall, 20 CTRL, 23 OB, and 19 WL females followed
nutritional protocol. Females and food on the grid were
weighed twice a week. Food intake (FI) was calculated as
(food day n (g) − food day 0 (g))/n days, with 3.85 kcal/g
for CD and 5.24 kcal/g for HFD. FI-to-body-weight ratio
(kcal/kg of body weight/day) was calculated for each
mouse. Measurement of fasting cholesterolemia, gly-
caemia, and oral glucose tolerance test (OGTT) were per-
formed at age 13 and 22 weeks (following 2 and 4 months
of diet).
Females were mated individually with randomly
assigned, chow-fed (Special Diets Services, Witham, Essex,
England; #801030 RM3A) 8–9-week-old males (n = 12).
The presence of vaginal plug represented embryonic day
0.5 (E0.5). If no plug was observed, females were mated
with another male according to their oestrus cycle. All
females were mated between 23 and 30 weeks of age and
respective diets were maintained throughout mating
period and gestation. Body weight of pregnant females
was recorded at E0.5 and E18.5. Gestational weight gain
was calculated as (body weight at E18.5 (g) − body weight
at E0.5 (g))/body weight at E0.5 (g). Pregnant CTRL
(n = 14), OB (n = 11), and WL (n = 17) females were
weighed and sacrificed by cervical dislocation at E18.5.
Tissue sampling was performed on a table maintained at
4 °C. Fetuses and placentas were removed from the uter-
ine horn and placed in a solution of PBS 1×. Maternal car-
casses (bodies without the uterus, fetuses, and placentas)
were weighed, and proper maternal body weight gain was
calculated as (carcass weight at sacrifice (g) − body weight
at E0.5 (g))/body weight at E0.5 (g). Fetal development
stage was in accordance with the “Theiler Staging Criteria
for Mouse Embryo Development” (TS 26). One CTRL
fetus and one OB fetus were removed from analysis and
tissue collection because of placental necrosis associated
with weak fetal weight. Fetal sex was determined by visual
examination of the gonads. Fetuses and placentas were
weighed (36 CTRL females (F) and 39 CTRL males (M);
35 OB F and 39 OB M; 61 WL F and 58 WL M). Maternal
group did not alter the sex ratios of the litters (proportion
test: p = 0.81; CTRL 48 % F, 52 % M; OB 47 % F, 53 % M;
WL 51 % F, 49 % M). The placental labyrinth and junc-
tional zone were separated and collected, along with the
fetal liver. Tissue samples were snap-frozen in liquid ni-
trogen and stored at −80 °C.
Experimental procedures
Fasting blood glucose levels were measured in all fe-
males (20 CTRL, 23 OB, 19 WL). OGTTs were per-
formed in a subset of females on a HFD, which showed
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a maximal body weight and weight gain (n = 11–12 per
group) and in CTRL females within an average range of
weight. After 6 h of fasting (8:00 a.m. to 2:00 p.m.), a
bolus of glucose (2 g/kg of body weight) was delivered
into the stomach of conscious mice with a gavage nee-
dle. Tail vein blood glycaemia was measured in dupli-
cates using an Accu-Chek Performa blood glucose meter
(Roche diagnostics GmbH, Germany) at time 0, 20, 40,
60, 90, and 120 min. This protocol was described as the
best discriminating glucose tolerance between HFD vs.
CD mice [89].
Submandibular vein blood (300 μl) from conscious
mice was collected in heparinized tubes (Choay heparin,
Sanofi-aventis, Paris, France) after 6 h of fasting. Blood
samples were centrifuged for 10 min at 1500g at 20 °C.
Plasma was collected and stored at −20 °C. Total choles-
terol plasma levels were measured by colorimetric dos-
age on Vitros system in Ambroise Paré Hospital
(Boulogne-Billancourt, France).
Statistical analysis of physiological data
All analyses were performed with the R statistical soft-
ware. For the entire preconceptional period, analyses
were performed on all mice (20 CTRL, 23 OB, 19 WL).
After mating, analyses were restricted to pregnant fe-
males (14 CTRL, 11 OB, 17 WL) and their litters. Linear
mixed models were used to model the evolution of pa-
rameters such as weight, food intake, and food efficiency
with time, using the lmer function of the lme4 package
in R [90]. Estimates of the slopes for each parameter
were reported as “β.” Reported p values were obtained
with a likelihood ratio test, thanks to the lrtest function
of the lmtest package [91]. ANOVA was used to test dif-
ferences at each time point, thanks to the aov function.
Reported p values were obtained with a likelihood ratio
test, thanks to the lrtest function of the lmtest package
[91]. We performed complete case analyses (i.e., we re-
moved all missing data for each individual, none were im-
puted). All p values were adjusted for multiple comparisons
using the p.adjust function with BH correction [92]. If sig-
nificance was found, Tukey’s post hoc test was used to de-
termine which groups differ from one another. Effect size
was reported as the proportion R2 of the variance in the
variable of interest (e.g., body weight, cholesterol, fetal
weight) that is explained by maternal group, among the
variance not already explained by the covariates. For most
variables of interest, groups showed unequal variances.
Therefore, investigated parameters were Box-Cox trans-
formed, using the powerTransform and bcPower functions
of the car package [93]. This function estimates a trans-
formation for the variable z from the family of transforma-
tions indexed by the parameter lambda that makes the
residuals from the regression of the transformed z on the
predictors as close to normally distributed as possible. We
used Pearson’s product moment correlation coefficient to
test a correlation between fetal weight and placental weight.
To adjust for factor “mother,” we conducted a regression of
fetal weight on mother and a regression of placental weight
on mother. The correlation test was performed on the re-
siduals of both models. We used a proportion test to deter-
mine differences in sex ratios in the offspring. We
calculated a proportion of SGA fetuses as described previ-
ously, using Z-score of 1.28 [94]. Logistic regression was
used to see the impact of maternal group on the odds of
being SGA, using the SGA status of the fetus as the re-
sponse variable (0 = not SGA and 1 = SGA) and age, sex,
and litter size as explanatory variables. Data are represented
as Tukey’s boxplots indicating the median, 25th, and 75th
percentiles. Whiskers indicate the 5th and 95th percentiles.
Outliers are shown as dots.
Expression analysis
RNA extraction and DNAse treatment
Only litters with 6–9 fetuses were included in the ex-
pression analysis. For each fetus, total RNA was ex-
tracted from 20 to 50 mg of the placental labyrinth,
junctional zone, or fetal liver. Tissue was reduced to a
powder in liquid nitrogen and homogenized in 500 μl of
TRIZOL reagent in Mixer Mill MM300 (Qiagen) with
one tungsten ball for 2 min at 20 Hz twice. Then, RNA
was extracted according to the manufacturer’s instructions
for RNA isolation (Life Technologies). The aqueous phase
containing RNA was collected using Phase Lock Gel Heavy
tubes (5 Prime, Hamburg, Germany). The extracted RNA
was resuspended in 100 μl of RNase-free water and stored
at −20 °C. RNA concentration and purity (A260/A280) was
measured using NanoDrop spectrophotometer (NanoDrop
Technologies), and a DNase treatment was performed
(DNA-free kit, AM1906, Ambion, Life Technologies). The
quality of RNA samples was assessed using Bio-Analyzer
Agilent 2100 (Agilent Technologies). The RNA integrity
number (RIN) of all samples was between the range of 8.8
and 10. For each tissue, 2.5 μg of RNA per fetal sample was
pooled according to litter, sex, and maternal diet (n = 8
CTRL F, 8 CTRL M, 7 OB F, 7 OB M, 8 WL F, 8 WL M).
Reverse transcription
Six hundred nanograms of RNA was converted into
cDNA using the High Capacity cDNA Reverse Tran-
scription Kit with RNase Inhibitor (Applied Biosystems)
according to the manufacturer’s recommendations. Re-
verse transcription were performed in duplicates that
were pooled and stored at +4 °C.
Quantitative real-time PCR
Gene expression was quantified using custom TaqMan
low-density arrays (TLDAs) (Applied Biosystems). Each
array consisted of a 384-well microfluidic card preloaded
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with primer sets and 6-FAM-labeled TaqMan probes.
The format we chose (96a; Cat. No. 4342261) contained
four samples per card; for each sample, the expression of
96 genes was measured, including four control assays.
The first set of 60 target genes included genes implicated
in epigenetic processes and the second set of 32 target
genes included genes implicated in placental/hepatic de-
velopment or energetic metabolism (Additional file 3).
We studied the expression of five DNA methyltransfer-
ases (DNMTs), 18 histone deacetylases (HDACs), seven
KMTs, seven KDMs, nine lysine acetyltransferases
(KATs), five methyl-binding domain proteins (MBDs),
two bromodomain proteins (BRDs), four protein argin-
ine N-methyltransferases (PRMTs), and three enzymes
of DNA hydroxymethylation (TETs). All assays and their
assay ID numbers are listed in Additional file 2: Table
S1. All probes spanned a gene, an exon-exon junction,
except for the following assays: Actb (Mm00607939_s1),
Mrpl32 (Mm00777741_sH), Bdnf (Mm04230607_s1),
Cebpα (Mm00514283_s1), and Cebpβ (Mm00843434_s1),
where primers and probes mapped within a single exon.
In addition, the following assays may detect genomic DNA:
18S (Hs99999901_s1), Hdac1 (Mm02391771_g1), Hdac10
(Mm01308118_g1), and Mecp2 (Mm01193537_g1). Thus,
all samples were treated with DNase. The experiment was
performed on the BRIDGE-ICE platform (INRA, Jouy-en-
Josas, France) according to the manufacturer’s instruc-
tions. Four samples were run on each TLDA card in
simplicates. Each sample reservoir on the card was loaded
with 100 μl of the reaction mix: cDNA template (600 ng)
mixed with TaqMan Gene Expression Master Mix (Ap-
plied Biosystems). After centrifugation (twice 1 min at
1200 rpm, Heraeus Multifuge 3S Centrifuge), the wells
were sealed with a TLDA Sealer (Applied Biosystems).
Real-time PCR amplification was performed on the
7900HT Real-Time PCR System (Applied Biosystems)
using SDS 2.4 software with standard conditions: 2 min
50 °C, 10 min 94.5 °C, 30 s 97 °C (40 cycles), 1 min
59.7 °C.
Normalization of expression level
Six potential reference genes were tested on the fetal
liver and placental tissue samples: Eif4a2 (eukaryotic
translation initiation factor 4A2), ActB (Actin beta), Tbp
(TATA box-binding protein), Gapdh (glyceraldehyde-3-
phosphate dehydrogenase), Mrpl32 (mitochondrial ribo-
somal protein L32), and Sdha (succinate dehydrogenase
complex, subunit A, flavoprotein). Using the GeNorm
software, ActB, Sdha, and Mrpl32 were chosen for
normalization of expression levels [95]. Threshold cycle
(Ct) values were calculated with the ExpressionSuite
v1.0.3 software (Applied Biosystems). The detection
threshold was set manually for all genes and was the
same for each assay in all tissues. Ct = 39 was used as
the cutoff: above this value, expression level was set to 0.
Genes were assigned as non-amplified (NA) if more than
15 % of samples were NA. All NA genes (Additional file 4:
Table S2; 12 in the fetal liver, 6 in the placental labyrinth,
and 3 in the junctional zone) were removed from the ana-
lysis. Normalization was performed independently for
same-sex samples within each maternal group (CTRL F,
CTRL M, OB F, OB M, WL F, WL M). For each of these
groups, Ct[ref] was the mean of the three Ct values of the
reference genes. Then, expression level of target genes
was calculated as 2−(Ct[target gene] −Ct[ref]), as previously de-
scribed [96].
Hierarchical clustering
For each tissue, transcription values of each target gene
were averaged across same-sex samples within each ma-
ternal group (CTRL F, CTRL M, OB F, OB M, WL F,
WL M). Only genes with expression >0 were taken into
account (80 in the liver, 86 in the labyrinth, and 89 in
the junctional zone). Missing Ct values were imputed (7
in the liver, 7 in the labyrinth, and 4 in the junctional
zone out of 4416 values per tissue), assigning the mean
Ct value of the samples with similar sex and maternal
diet. Then, hierarchical clustering was performed using
Pearson’s correlation coefficient as distance function and
Ward as linkage method.
Statistical analysis of TLDA expression study
Analysis was performed with the R statistical software.
For each gene, we compared the expression values be-
tween males and females within each maternal group.
As we did not detect an effect of sex on the expression
for any of the studied genes (except for Kdm5d and Uty,
both located on Y chromosome), we pooled males and fe-
males within each maternal group. Pairwise comparisons
of maternal groups were conducted using a permutation
test, as implemented in the oneway_test function of the
coin package in R [97]. For each set of tests (i.e., all tested
genes for a given pair of maternal groups), p values were
adjusted for multiple testing as proposed by Benjamini
and Hochberg [92]. Differences were considered signifi-
cant when Padj < 0.05. Data are shown as means ± St. Dev
or as Tukey’s boxplots.
Additional files
Additional file 1: Supplementary Figures S1 to S6. Food intake (FI) to
body weight (BW) ratio in females during the preconceptional period. (a)
P < 0.05 OB vs. CTRL, (b) P < 0.05 WL vs. CTRL, (c) P < 0.05 WL vs. OB.
n = 18–20 CTRL, 23 OB, 17–19 WL. Figure S2. Fetal weight as a function
of litter size in dams at E18.5. Both sexes were combined as there was no
effect of sex on fetal weight. Figure S3. Placental weight as a function of
litter size and sex at E18.5. Figure S4. Effect of maternal age on fetal
parameters. (A) Relationship between maternal age and fetal weight. (B)
Relationship between maternal age and fetal-weight-to-placental-weight
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ratio index (FPI). For statistical analysis, see text. Figure S5. Distribution of
fetal weight in CTRL, OB, and WL dams at E18.5. CTRL dams are represented
in black, WL dams in brown, and OB dams in blue. The red line represents
the 10th percentile of CTRL population. Figure S6. Relationship between
fetal and placental weight in female and male offspring at E18.5. For
statistical analysis, see text and “Methods” section. M: males, F: females.
Additional file 2: List of the gene symbol and name, and the
design strand and TaqMan® Gene Expression Assay IDentification
reference for the 96 genes studied on the Custom TLDA.
Additional file 3: Description of the selection criteria of genes for
the custom TLDA design and related bibliographic references.
Additional file 4: Expression level and adjusted P values of 92
genes in the fetal liver, placental labyrinth, and junctional zone. We
assessed the expression level of 60 epigenetic machinery genes and 32
genes implicated in metabolism or development in CTRL, OB, and WL
females at E18.5 using TaqMan low-density arrays. Data are represented as
mean expression levels ± St.Dev. *—differentially expressed genes.
NA—non-amplified. Significant differences (Padj < 0.05) are indicated in red.
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